You are here

A user-friendly microfluidic chip for anti-epileptogenic drug screening

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41NS108895-01
Agency Tracking Number: R41NS108895
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 101
Solicitation Number: PA17-303
Timeline
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-01
Award End Date (Contract End Date): 2019-08-31
Small Business Information
27574 COMMERCE CENTER DR STE 137
Temecula, CA 92590-2535
United States
DUNS: 026927928
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ANNE TAYLOR
 (626) 532-0396
 amtaylor@unc.edu
Business Contact
 BRAD TAYLOR
Phone: (626) 228-8682
Email: brad.xona@gmail.com
Research Institution
 UNIVERSITY OF NORTH CAROLINA AT CHAPEL H
 
ROOM 102 CARRINGTON HALL
CHAPEL HILL, NC 27599
United States

 Domestic Nonprofit Research Organization
Abstract

New pharmacological treatments for epilepsy will be discovered through the development of new screening
platforms that are rapidreliableand can identify novel disease modifying therapiesor anti epileptogenic
treatmentsXona MicrofluidicLLCXonais in a unique position to provide such screening tools and services
for epilepsy researchXona focuses on the development of microfluidic platforms for neuron cell culture and
provides devices that allow compartmentalization and fluidic isolation of axons and or dendritesand somataWe have patented technology and have sold devices to hundreds of labs world wideincluding many
pharmaceutical laboratoriesEpileptogenesis induces an imbalance in inhibitory excitatory circuits within the
brainleading to hyper excitability and seizuresA common cause of epilepsy is brain damage due to traumatic
brain injury or strokeoften involving pyramidal cells within the hippocampusOur academic partners at UNC
recently demonstrated the reliable induction of hyper excitability in pyramidal cells using a standard neuron
deviceSNDconfiguration microfluidic chamber in response to axotomyNagendran et alNature
CommunicationsThis hyper excitabilitywhich involves an imbalance of excitation and inhibitiondevelops reliably and with a delayat two days after axotomyIn separate NIH fundingwe dramatically
improved the manufacturability of our platform leading to fully assembledmore robust devicesHere we will
develop a new platform optimized for screening anti epileptogenic compounds to provide a much needed
screening service to researchers as well as current and future pharmaceutical customersAimfocuses on
developing a new injection moldable platform optimized to increase axon damage in a multi well formatAimwill lead to the development of an immunoassay to rapidly measure inhibitory excitatory balance within this
microfluidic screening platform PUBLIC HEALTH RELEVANCEThis project will provide an important resource for the development of more
effective epilepsy treatmentsKnowledge gained from this project has the potential to improve therapies and
recovery outcomes for epilepsy

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government